


Serial No. 09/996,641
Filed: November 28, 2001
Response to Office Action

CLAIM AMENDMENTS

Claim 1: (cancelled).

Claim 2: (currently amended) A method of treating a disease responsive to modulation of the mGluR5a receptors comprising administering to a person in need of such treatment a therapeutically effective amount of a compound of the formula




I-A

wherein R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen, lower alkoxy, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl, ~~unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl;~~

R, and R' and R'' are independently selected from the group consisting of, hydrogen or lower alkyl;

and B is selected from the group consisting of



wherein R⁶ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR and halogen;

R⁷ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR', halogen, nitro, unsubstituted heteroaryl and heteroaryl substituted by lower alkyl or cycloalkyl;

R⁸ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-OH, (CH₂)_n-C(O)OR'' and aryl;

R⁹ is lower alkyl;

R¹⁰ is selected from the group consisting of hydrogen, lower alkyl and halogen;

R¹¹ is selected from the group consisting of hydrogen and alkyl;

R¹² is (CH₂)_n-N(R)-C(O)-lower alkyl;

R¹³ is selected from the group consisting of hydrogen or lower alkyl;

R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-halogen or lower alkoxy;


Serial No. 09/996,641
Filed: November 28, 2001
Response to Office Action

R^{18} , R^{19} and R^{20} are independently selected from the group consisting of, hydrogen, lower alkyl, $-(CH_2)_n$ -halogen and lower alkoxy;
 R^{21} — is selected from the group consisting of hydrogen and lower alkyl;
 R^{22} — is selected from the group consisting of hydrogen, lower alkyl and lower alkyl carrying at least one substituent selected from hydroxy or halogen;
 R^{23} — is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl and nitro;
 R^{24} , R^{25} and R^{26} are independently selected from the group consisting of hydrogen and lower alkyl;
 n is 0, 1, 2, 3, 4, 5 or 6;
 X selected from the group consisting of $-CH_2-$, $-O-$ and $-S-$; and
 Y is selected from the group consisting of $-CH=$ and $-N=$;
or a pharmaceutically acceptable salt thereof.

Claim 3: (cancelled).

Claim 4: (cancelled).

Claim 5: (currently amended) A method of treating pain comprising administering to a person in need of such treatment a therapeutically effective amount of a compound of the formula




I-A

wherein R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen, lower alkoxy, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl, ~~unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl;~~

R, and R' and R'' are independently selected from the ~~group consisting of~~ hydrogen or lower alkyl;

and B is ~~selected from the group consisting of~~



wherein R⁶ is selected from the group consisting of hydrogen, lower alkyl, $(CH_2)_n-C(O)OR$ and halogen;

R⁷ is selected from the group consisting of hydrogen, lower alkyl, $(CH_2)_n-C(O)OR'$, halogen, nitro or unsubstituted heteroaryl and heteroaryl substituted by lower alkyl or cycloalkyl;

R⁸ is selected from the group consisting of hydrogen, lower alkyl, $(CH_2)_n-OH$, $(CH_2)_n-C(O)OR''$ and aryl;

R⁹ is lower alkyl;

R¹⁰ is selected from the group consisting of hydrogen, lower alkyl and halogen;

R¹¹ is selected from the group consisting of hydrogen and alkyl;

R¹² is $(CH_2)_n-N(R)-C(O)$ lower alkyl;

R¹³ is selected from the group consisting of hydrogen and lower alkyl;

R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, lower alkyl, $(CH_2)_n$ halogen and lower alkoxy;

Serial No. 09/996,641
Filed: November 28, 2001
Response to Office Action

R^{18} , R^{19} and R^{20} are independently selected from the group consisting of hydrogen, lower alkyl, -
(CH₂)_n-halogen and lower alkoxy;

R^{21} — ~~is selected from the group consisting of hydrogen and lower alkyl;~~

R^{22} — ~~is selected from the group consisting of hydrogen, lower alkyl and lower alkyl carrying at
least one substituent selected from hydroxy or halogen;~~

R^{23} — ~~is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl or nitro;~~

R^{24} , R^{25} and R^{26} ~~are independently selected from the group consisting of hydrogen and lower
alkyl;~~


n is 0, 1, 2, 3, 4, 5 or 6;

X selected from the group consisting of -CH₂-, -O- and -S-; and

Y is selected from the group consisting of -CH= and -N=;

or a pharmaceutically acceptable salt thereof.

Claim 6: (currently amended) A method of treating anxiety or depression comprising
administering to a person in need of such treatment a therapeutically effective amount of a
compound of the formula




I-A

wherein R^1 , R^2 , R^3 , R^4 and R^5 are independently selected from the group consisting of hydrogen, lower alkyl, $-(CH_2)_n$ -halogen, lower alkoxy, $-(CH_2)_n$ -NRR', $-(CH_2)_n$ -N(R)-C(O)-lower alkyl, and aryl, ~~unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl;~~

R , and R' ~~and R''~~ are independently selected from ~~the group consisting of~~ hydrogen or lower alkyl;

and B is ~~selected from the group consisting of~~



wherein R^6 is ~~selected from the group consisting of~~ hydrogen, lower alkyl, $-(CH_2)_n$ -C(O)OR and halogen;

R^7 is ~~selected from the group consisting of~~ hydrogen, lower alkyl, $-(CH_2)_n$ -C(O)OR', halogen, nitro or unsubstituted heteroaryl and heteroaryl substituted by lower alkyl or cycloalkyl;

R^8 is ~~selected from the group consisting of~~ hydrogen, lower alkyl, $-(CH_2)_n$ -OH, $-(CH_2)_n$ -C(O)OR'' and aryl;

R^9 is lower alkyl;

Serial No. 09/996,641
Filed: November 28, 2001
Response to Office Action

R^{10} — is selected from the group consisting of hydrogen, lower alkyl and halogen;
 R^{11} — is selected from the group consisting of hydrogen and alkyl;
 R^{12} — is $(CH_2)_n-N(R)-C(O)$ lower alkyl;
 R^{13} — is selected from the group consisting of hydrogen and lower alkyl;
 R^{14} , R^{15} , R^{16} and R^{17} are independently selected from the group consisting of hydrogen, lower alkyl, $(CH_2)_n$ -halogen and lower alkoxy;
 R^{18} , R^{19} and R^{20} are independently selected from the group consisting of hydrogen, lower alkyl, $(CH_2)_n$ -halogen and lower alkoxy;
 R^{21} — is selected from the group consisting of hydrogen and lower alkyl;
 R^{22} — is selected from the group consisting of hydrogen, lower alkyl and lower alkyl carrying at least one substituent selected from hydroxy or halogen;
 R^{23} — is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl or nitro;
 R^{24} , R^{25} and R^{26} are independently selected from the group consisting of hydrogen and lower alkyl;
n is 0, 1, 2, 3, 4, 5 or 6;
X selected from the group consisting of $-CH_2-$, $-O-$ and $-S-$; and
Y is selected from the group consisting of $-CH=$ and $-N=$;
or a pharmaceutically acceptable salt thereof.


Claim 7: (cancelled).

Claim 8: (cancelled).

Claim 9: (cancelled).

Claim 10: (cancelled).

Claim 11: (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-A




I-A

wherein R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen, lower alkoxy, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl;

R and R' are independently selected from hydrogen or lower alkyl;

and B is



wherein

R¹⁸, R¹⁹ and R²⁰ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen and lower alkoxy;

Serial No. 09/996,641
Filed: November 28, 2001
Response to Office Action

n is 0, 1, 2, 3, 4, 5 or 6;


X selected from the group consisting of -CH₂-, -O- and -S-; and

Y is selected from the group consisting of -CH= and -N=;

or a pharmaceutically acceptable salt thereof and a pharmaceutically inert carrier.

Claim 12: (cancelled).

Claim 13: (currently amended) A compound of formula




I-A

wherein

R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen, lower alkoxy, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl; ~~unsubstituted heteroaryl and heteroaryl substituted by one or more lower alkyl;~~

~~R₁, R₂, R₃, R₄ and R₅~~ are independently selected from the group consisting of hydrogen ~~and~~ or lower alkyl;

~~B~~ is selected from the group consisting of



wherein

~~R⁶ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR and halogen;~~

~~R⁷ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-C(O)OR', halogen, nitro, unsubstituted heteroaryl and heteroaryl substituted by lower alkyl or cycloalkyl;~~

~~R⁸ is selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-OH, (CH₂)_n-C(O)OR'' and aryl;~~

~~R⁹ is lower alkyl;~~

~~R¹⁰ is selected from the group consisting of hydrogen, lower alkyl and halogen;~~

~~R¹¹ is selected from the group consisting of hydrogen and alkyl;~~

~~R¹² is (CH₂)_n-N(R)-C(O)-lower alkyl;~~

~~R¹³ is selected from the group consisting of hydrogen and lower alkyl;~~

Serial No. 09/996,641
Filed: November 28, 2001
Response to Office Action

~~R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are independently selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-halogen or lower alkoxy;~~

~~R¹⁸, R¹⁹ and R²⁰ are independently selected from the group consisting of hydrogen, lower alkyl, (CH₂)_n-halogen and lower alkoxy;~~

~~R²¹ is selected from the group consisting of hydrogen and lower alkyl;~~

~~R²² is selected from the group consisting of hydrogen, lower alkyl and lower alkyl substituted by at least one substituent selected from hydroxy or halogen;~~

~~R²³ is selected from the group consisting of hydrogen, lower alkyl, lower alkanoyl and nitro;~~

~~R²⁴, R²⁵ and R²⁶ are independently selected from the group consisting of hydrogen or lower alkyl;~~

~~n is 0, 1, 2, 3, 4, 5 or 6;~~

~~X is selected from the group consisting of -CH₂-, -O- and -S-; and~~

~~Y is selected from the group consisting of -CH= and -N=;~~

~~or a pharmaceutically acceptable salt thereof;~~

~~with the exception of~~

~~1-methyl-2-phenylethynyl-1H-imidazole,~~

~~1-methyl-2-(4-methoxy-phenylethynyl)-1H-imidazole,~~

~~1-methyl-5-phenylethynyl-1H-imidazole, and~~

~~1-methyl-4-phenylethynyl-1H-imidazole.~~

Claim 14: (cancelled).

Claim 15: (cancelled).

Claim 16: (cancelled).

Serial No. 09/996,641
Filed: November 28, 2001
Response to Office Action

Claim 17: (cancelled).

Claim 18: (cancelled).

Claim 19: (original) A compound selected from the group consisting of
3-phenylethynyl-4H-5-thia-2,6,9b-triaza-cyclopenta[a]naphthalene and
3-phenylethynyl-4H-5-oxa-2,9b-diaza-cyclopenta[a]naphthalene.

Claim 20: (cancelled).

Claim 21: (cancelled).

Claim 22: (cancelled).

Claim 23: (cancelled).

Claim 24: (cancelled).

Claim 25: (cancelled).

Claim 26: (cancelled).

Claim 27: (cancelled).


Claim 28: (cancelled).

Claim 29: (cancelled).

Claim 30: (cancelled).

Claim 31: (cancelled).

Claim 32: (new) A process for the preparation of a compound of formula




I-A

wherein R¹, R², R³, R⁴ and R⁵ are independently selected from the group consisting of hydrogen, lower alkyl, -(CH₂)_n-halogen, lower alkoxy, -(CH₂)_n-NRR', -(CH₂)_n-N(R)-C(O)-lower alkyl, and aryl;

R and R' are independently selected from hydrogen or lower alkyl;

and B is

Serial No. 09/996,641
 Filed: November 28, 2001
 Response to Office Action



wherein


R^{18} , R^{19} and R^{20} are independently selected from the group consisting of hydrogen, lower alkyl, -
 $(CH_2)_n$ -halogen and lower alkoxy;

n is 0, 1, 2, 3, 4, 5 or 6;

X selected from the group consisting of $-CH_2-$, $-O-$ and $-S-$; and

Y is selected from the group consisting of $-CH=$ and $-N=$,

which process comprises reacting a compound of the formula



with a compound of formula



wherein X signifies halogen or trifluoromethanesulfonyl.